ImmuPharma (LON:IMM) Stock Price Up 27.3% - Here's What Happened

Key Points

• ImmuPharma plc's share price surged by 27.3% during trading on Saturday, reaching as high as GBX 12.75 ($0.17) before settling at GBX 12.60 ($0.17).
• The company's stock reflects a market capitalization of £63.34 million with a P/E ratio of -1,415.73 and is actively traded with 4,543,810 shares changing hands, a notable decrease from its average daily volume.
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases, with its lead program, P140 (Lupuzor™), showing promise in treating Lupus and potentially other related conditions.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price rose 27.3% during trading on Saturday . The stock traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). Approximately 4,543,810 shares changed hands during trading, a decline of 46% from the average daily volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Stock Performance

The stock has a market capitalization of £63.34 million, a P/E ratio of -1,415.73 and a beta of 1.53. The firm has a 50-day moving average price of GBX 7.92 and a 200 day moving average price of GBX 4.36.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, equities analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.